Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Kidney Transplant Rejection Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The kidney transplant rejection market size has experienced significant growth in recent years. Its valuation is anticipated to increase from $3.51 billion in 2025 to $3.76 billion in 2026, growing at a compound annual growth rate (CAGR) of 7.2%. This historical expansion can be attributed to an increase in kidney transplant procedures, advancements in histopathological assessment techniques, wider availability of immunosuppressive drugs, the expansion of transplant center networks, and improved post-transplant patient survival rates.
The kidney transplant rejection market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $5.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This projected growth can be ascribed to several factors, including the escalating demand for tailored immunosuppression approaches, the wider embrace of molecular diagnostics, the broadening application of precision medicine in transplant management, an intensified emphasis on achieving prolonged graft survival, and augmented investment in transplant monitoring solutions. Key trends anticipated during this period encompass the growing integration of biomarker-driven rejection monitoring, a surge in genomics-based diagnostic techniques, the ongoing refinement of immunosuppressive therapy regimens, the development of more non-invasive methods for rejection surveillance, and a heightened focus on the prompt identification of chronic rejection.
Get A Free Sample Report With In-Depth Market Insights:
Kidney Transplant Rejection Market Demand Drivers: What’s Powering Industry Growth?
The increasing occurrence of end-stage renal disease is anticipated to drive expansion in the kidney transplant rejection market in the future. End-stage renal disease (ESRD) signifies the ultimate, irreversible phase of chronic kidney disease where kidneys are unable to function properly without either dialysis or a kidney transplant. The prevalence of end-stage renal disease is growing, attributed to the escalating rates of chronic conditions such as diabetes and hypertension, which gradually impair kidney function, culminating in kidney failure. Kidney transplant rejection necessitates sophisticated monitoring and treatment strategies, thereby directly aiding in the management of end-stage renal disease by ensuring the viability of transplanted kidneys and the preservation of patient kidney health. For example, data from September 2024, provided by the National Institute of Diabetes and Digestive and Kidney Diseases, a US government body, indicated that in 2023, over 808,000 individuals in the United States were living with end-stage kidney disease (ESKD), also referred to as end-stage renal disease (ESRD). Of these, 68% were undergoing dialysis, while 32% had received a kidney transplant. Consequently, the increasing occurrence of end-stage renal disease is fueling the expansion of the kidney transplant rejection market.
Kidney Transplant Rejection Market Segment Analysis: What Are The Core Market Categories?
The kidney transplant rejection market covered in this report is segmented –
1) By Rejection Type: Chronic Rejection; Acute Rejection
2) By Treatment: Immunosuppressive Drugs; Antibody-Mediated Rejection Therapies
3) By Diagnostic Approach: Biomarker-Based Diagnostics; Genomics-Based Diagnostics
4) By Therapeutics: Small Molecule Inhibitors; Biologic Therapies
5) By End-Users: Transplant Centers Or Hospitals; Diagnostic Laboratories; Pharmacies
Subsegments:
1) By Chronic Rejection: Antibody Mediated Chronic Rejection; Chronic Allograft Nephropathy; Interstitial Fibrosis And Tubular Atrophy; Vascular Chronic Rejection; Mixed Chronic Rejection
2) By Acute Rejection: Cellular Acute Rejection; Antibody Mediated Acute Rejection; Hyperacute Rejection; Mixed Acute Rejection; Vascular Acute Rejection
Kidney Transplant Rejection Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies in the kidney transplant rejection market are concentrating on developing advanced diagnostic methods, such as noninvasive urinary biomarker testing, to facilitate faster, safer, and more precise identification of transplant rejection. This noninvasive urinary biomarker testing examines urine specimens to pinpoint molecular indicators of kidney inflammation or rejection, assisting medical professionals in promptly and safely recognizing transplant complications, thereby circumventing the necessity for intrusive biopsies. For example, in May 2024, Thermo Fisher Scientific Inc., a US-based biotechnology corporation, introduced the CXCL10 testing service, a pioneering diagnostic instrument designed for individuals receiving kidney transplants. The CXCL10 assay identifies the CXCL10 chemokine present in urine, a substance linked to both early transplant rejection and inflammatory responses. It provides results within 24 hours, facilitating more rapid clinical judgments, lessening the requirement for superfluous biopsies, and enhancing patient ease through the use of noninvasive sample acquisition. Conceived and validated by Thermo Fisher’s One Lambda Laboratories, the analytical method merges strong sensitivity and specificity with straightforward application in clinical environments, fostering enhanced post-transplant management and improved patient prognoses.
Kidney Transplant Rejection Market Company Landscape And Competitive Strategy
Major companies operating in the kidney transplant rejection market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., ChugAI Pharmaceutical Co. Ltd., Eurofins Scientific SE, Illumina Inc., Natera Inc., CareDx Inc., Azurity Pharmaceuticals Inc., Insight Molecular Diagnostics, and RenalytixAI plc.
View The Full Kidney Transplant Rejection Market Report:
Kidney Transplant Rejection Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the kidney transplant rejection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney transplant rejection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
